| pubmed-article:10678352 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:10678352 | lifeskim:mentions | umls-concept:C1332128 | lld:lifeskim |
| pubmed-article:10678352 | lifeskim:mentions | umls-concept:C0056997 | lld:lifeskim |
| pubmed-article:10678352 | lifeskim:mentions | umls-concept:C1515035 | lld:lifeskim |
| pubmed-article:10678352 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:10678352 | pubmed:dateCreated | 2000-2-29 | lld:pubmed |
| pubmed-article:10678352 | pubmed:abstractText | Gene therapy is a novel therapeutic approach that might soon improve the prognosis of some cancers. We investigated the feasibility of cytosine deaminase (CD) suicide gene therapy in a model of peritoneal carcinomatosis. DHD/K12 colorectal adenocarcinoma cells transfected in vitro with the CD gene were highly sensitive to 5-fluorocytosine (5-FC), and a bystander effect could also be observed. Treating CD+ cells with 5-FC resulted in apoptosis as detected by terminal deoxynucleotidyltransferase-mediated deoxyuridine triphosphate nick-end labeling. In vitro, several human cell lines derived from ovarian or colorectal carcinomas, as well as the rat glioblastoma 9 L cell line, responded to CD/5-FC and showed a very strong bystander effect. 5-FC treatment of peritoneal carcinomatosis generated in syngeneic BDIX rats by CD-expressing DHD/K12 cells led to a complete and prolonged response and to prolonged survival. Our study thus demonstrated the efficacy of CD suicide gene therapy for the treatment of peritoneal carcinomatosis. | lld:pubmed |
| pubmed-article:10678352 | pubmed:language | eng | lld:pubmed |
| pubmed-article:10678352 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10678352 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:10678352 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10678352 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10678352 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10678352 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10678352 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10678352 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10678352 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:10678352 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:10678352 | pubmed:issn | 0929-1903 | lld:pubmed |
| pubmed-article:10678352 | pubmed:author | pubmed-author:LopezMM | lld:pubmed |
| pubmed-article:10678352 | pubmed:author | pubmed-author:GielenJJ | lld:pubmed |
| pubmed-article:10678352 | pubmed:author | pubmed-author:FilletGG | lld:pubmed |
| pubmed-article:10678352 | pubmed:author | pubmed-author:BoursVV | lld:pubmed |
| pubmed-article:10678352 | pubmed:author | pubmed-author:MervilleM PMP | lld:pubmed |
| pubmed-article:10678352 | pubmed:author | pubmed-author:LechanteurCC | lld:pubmed |
| pubmed-article:10678352 | pubmed:author | pubmed-author:PrincenFF | lld:pubmed |
| pubmed-article:10678352 | pubmed:author | pubmed-author:HellinA CAC | lld:pubmed |
| pubmed-article:10678352 | pubmed:author | pubmed-author:Bentires-AljM... | lld:pubmed |
| pubmed-article:10678352 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:10678352 | pubmed:volume | 7 | lld:pubmed |
| pubmed-article:10678352 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:10678352 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:10678352 | pubmed:pagination | 20-6 | lld:pubmed |
| pubmed-article:10678352 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:10678352 | pubmed:meshHeading | pubmed-meshheading:10678352... | lld:pubmed |
| pubmed-article:10678352 | pubmed:meshHeading | pubmed-meshheading:10678352... | lld:pubmed |
| pubmed-article:10678352 | pubmed:meshHeading | pubmed-meshheading:10678352... | lld:pubmed |
| pubmed-article:10678352 | pubmed:meshHeading | pubmed-meshheading:10678352... | lld:pubmed |
| pubmed-article:10678352 | pubmed:meshHeading | pubmed-meshheading:10678352... | lld:pubmed |
| pubmed-article:10678352 | pubmed:meshHeading | pubmed-meshheading:10678352... | lld:pubmed |
| pubmed-article:10678352 | pubmed:meshHeading | pubmed-meshheading:10678352... | lld:pubmed |
| pubmed-article:10678352 | pubmed:meshHeading | pubmed-meshheading:10678352... | lld:pubmed |
| pubmed-article:10678352 | pubmed:meshHeading | pubmed-meshheading:10678352... | lld:pubmed |
| pubmed-article:10678352 | pubmed:meshHeading | pubmed-meshheading:10678352... | lld:pubmed |
| pubmed-article:10678352 | pubmed:meshHeading | pubmed-meshheading:10678352... | lld:pubmed |
| pubmed-article:10678352 | pubmed:meshHeading | pubmed-meshheading:10678352... | lld:pubmed |
| pubmed-article:10678352 | pubmed:meshHeading | pubmed-meshheading:10678352... | lld:pubmed |
| pubmed-article:10678352 | pubmed:meshHeading | pubmed-meshheading:10678352... | lld:pubmed |
| pubmed-article:10678352 | pubmed:meshHeading | pubmed-meshheading:10678352... | lld:pubmed |
| pubmed-article:10678352 | pubmed:meshHeading | pubmed-meshheading:10678352... | lld:pubmed |
| pubmed-article:10678352 | pubmed:meshHeading | pubmed-meshheading:10678352... | lld:pubmed |
| pubmed-article:10678352 | pubmed:meshHeading | pubmed-meshheading:10678352... | lld:pubmed |
| pubmed-article:10678352 | pubmed:year | 2000 | lld:pubmed |
| pubmed-article:10678352 | pubmed:articleTitle | Cytosine deaminase suicide gene therapy for peritoneal carcinomatosis. | lld:pubmed |
| pubmed-article:10678352 | pubmed:affiliation | Laboratory of Medical Chemistry/Medical Oncology, University of Liège, Belgium. | lld:pubmed |
| pubmed-article:10678352 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:10678352 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10678352 | lld:pubmed |
